2024-10-18 - Analysis Report
## Regeneron Pharmaceuticals Inc (REGN) Stock Analysis Report

**1. Performance Comparison:**

Regeneron Pharmaceuticals Inc (REGN) has accumulated a return of 92.09% compared to the S&P 500 (VOO) which has a return of 136.93%.  This results in a current divergence of -44.84%, meaning REGN has underperformed the S&P 500 by 44.84%. The relative divergence, which measures its position relative to the historical range, is 31.65%, indicating that the current underperformance is relatively moderate compared to its historical volatility.

**2. Recent Price Action:**

* **Closing Price:** $1007.96
* **5-day Moving Average:** $1010.91
* **20-day Moving Average:** $1039.67
* **60-day Moving Average:** $1106.25

The price is currently below all three moving averages, suggesting a short-term downtrend. 

**3. Technical Indicators:**

* **RSI:** 38.96:  This suggests that the stock is currently in oversold territory, although not extremely so.
* **PPO:** 0.05: A positive PPO value indicates bullish momentum, but the value is relatively low, indicating weak momentum.
* **Delta_Previous_Relative_Divergence:** -25.9:  A negative value means the stock's relative divergence has worsened in the last 20 days, further reinforcing the short-term downtrend.
* **Expected Return:** 0.0%: This indicates no expected outperformance against the S&P 500 over the next 5 years based on current information.

**4. Recent Earnings and Outlook:**

| Date        | EPS   | Revenue        |
|-------------|-------|----------------|
| 2024-08-01 | 13.25 | $3.55 Billion |
| 2024-05-02 | 6.7   | $3.15 Billion |
| 2023-11-02 | 9.48 | $3.36 Billion |
| 2023-08-03 | 9.05 | $3.16 Billion |
| 2024-08-01 | 9.05 | $3.16 Billion |

Regeneron has consistently exceeded revenue estimates in recent quarters, but earnings have fluctuated. The most recent earnings report for Q2 2024 showed a beat on both earnings and revenue, with EPS coming in at $13.25, exceeding expectations of $12.85.  While this suggests continued positive performance, it's important to note the volatility of the stock and the uncertain market outlook. 

**5. News and Recent Issues:**

Recent market sentiment towards REGN has been mixed, with some analysts citing strong performance in key products like Eylea and Dupixent, while others point to potential competition and slower growth in some areas.  

According to **FINBOLD**,  Regeneron is expected to benefit from its strong product portfolio, including its established ophthalmology drugs and expanding presence in atopic dermatitis, asthma, and other conditions.  The company's partnership with Sanofi is also seen as a positive factor for its long-term prospects. However, analysts are also noting that increased competition in the biopharmaceutical space could present a challenge, and they are closely watching the performance of new products like Libtayo.  

**6. Summary:**

Regeneron Pharmaceuticals Inc (REGN) is a leading biopharmaceutical company with a strong track record of innovation and market share in key therapeutic areas.  Recent earnings have been positive, but the stock is currently in a short-term downtrend and facing some headwinds from increased competition.  Although the company's long-term prospects remain strong, investors should monitor developments in its key product lines and market dynamics closely to assess its future performance potential.

**7.  Recommendations:**

Given the current market conditions and technical indicators, it's recommended that investors take a cautious approach to REGN at this time.  While the company's fundamentals remain strong, the short-term price action suggests a potential period of consolidation.  It's advisable to wait for signs of a clear reversal in the trend or a more positive market outlook before considering a significant investment position.